Study how immune cells affect fatty liver disease
Part of Digestive system clinical trials.
This study looks at how certain immune cells (“regulatory B cells”) may contribute to metabolic fatty liver disease. You might be able to join if you’re an adult with fatty liver but not pregnant and not on certain treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be older than 18 years
- Have been diagnosed with fatty liver using tests like imaging and labs
- Be willing to avoid joining if you are currently pregnant
- Do not have any known cancer (malignancy)
- Do not have type 1 diabetes or use statin medicines/other fatty-liver medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at what drives non-alcoholic fatty liver disease and how it affects the body, including immune-related changes. You may be invited if you have confirmed fatty liver disease or, alternatively, if you are a healthy person with no liver disease.
This study follows people who have been confirmed to have fatty liver disease seen on a liver sample. It aims to understand the condition over time and how different causes and health factors may affect it.
This study looks at how a type of immune cell (macrophage) in fat tissue processes lipids, and how that affects metabolism in people with different body weights. It may help us understand why some people with obesity develop diabetes and fatty liver while others do not.
This study looks at what factors predict liver inflammation, scarring (fibrosis), and health outcomes in people with long-term hepatitis B or fatty liver disease. The goal is to better understand who is more likely to worsen over time.
This study looks at adults with different long-term liver conditions that are associated with fatty liver. It helps researchers better understand these diseases and factors linked to them.
This study looks at how the liver's immune environment changes in people with non-alcoholic fatty liver disease (NAFLD) that has progressed to significant scarring. Researchers will use a liver biopsy to understand the inflammation better, which may lead to new treatments.
Hear when a new Non-Alcoholic Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.